Who invested in Affinia Therapeutics

One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Follow Affinia Therapeutics and see its new rounds in your feed.Start following

Funding summaryUpdated 27 Oct 2026

$40Mraised across 1 round since 2025, from 1 source

Latest round: Series C, $40MOct 2025
Investors: 6

See who backed them

The rounds

Oct 2025
Series C$40M
Source recordedSEC filing: $13M sold, first sale Sept 2025

Founders and team

From Affinia Therapeutics's own website: 4 on the team.

Rick ModiChief Executive Officer, Board Member
Rami DaoudChief Business and Financial Officer
Rob MayChief Technical Operations Officer
Sean P. NolanChairman of the Board

Everyone who backed them

New Enterprise AssociatesVC firm1round

RA Capital ManagementPrivate equity1round

Perceptive AdvisorsAsset manager1round

Eli LillyCorporate VC1round

TCGPrivate equity1round

TCG CrossoverVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Affinia Therapeutics

Who invested in Affinia Therapeutics?

Affinia Therapeutics's investors include New Enterprise Associates, RA Capital Management, Perceptive Advisors, Eli Lilly and TCG, and 1 more on record.

How much has Affinia Therapeutics raised?

Affinia Therapeutics has raised $40M across 1 round since 2025.

When did Affinia Therapeutics last raise?

Affinia Therapeutics's most recent round was a Series C of $40M in Oct 2025.

What was Affinia Therapeutics's biggest round?

Its most recent round, $40M in Oct 2025, is also its largest on record.

Who backed Affinia Therapeutics first?

Affinia Therapeutics's first round on record, in Oct 2025, was backed by New Enterprise Associates, RA Capital Management and Perceptive Advisors and 3 others.